{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:34:16Z","timestamp":1774380856689,"version":"3.50.1"},"reference-count":11,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","award":["18-358f"],"award-info":[{"award-number":["18-358f"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal - Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p> Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21\u2009months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch. <\/jats:p>","DOI":"10.1177\/20552173211013831","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T06:35:38Z","timestamp":1622615738000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients"],"prefix":"10.1177","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-8966","authenticated-orcid":false,"given":"ZYGJ","family":"van Lierop","sequence":"first","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AA","family":"Toorop","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-9996","authenticated-orcid":false,"given":"EME","family":"Coerver","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"},{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EAJ","family":"Willemse","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EMM","family":"Strijbis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"},{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NF","family":"Kalkers","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"},{"name":"Department of Neurology, OLVG, Amsterdam, the Netherlands"},{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Moraal","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3706","authenticated-orcid":false,"given":"F","family":"Barkhof","sequence":"additional","affiliation":[{"name":"epartment of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Institutes of Neurology and Healthcare Engineering, UCL, London, United Kingdom"},{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CE","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Killestein","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZLE","family":"van Kempen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"bibr1-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001355"},{"key":"bibr2-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.05.017"},{"key":"bibr3-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"bibr4-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.157"},{"key":"bibr5-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000904"},{"key":"bibr6-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007032"},{"key":"bibr7-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000719"},{"key":"bibr8-20552173211013831","doi-asserted-by":"crossref","unstructured":"Mancinelli CR, Scarpazza C, Cordioli C, et\u00a0al. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Mult Scler 2020: 1352458520946017.","DOI":"10.1177\/1352458520946017"},{"key":"bibr9-20552173211013831","doi-asserted-by":"crossref","first-page":"P3.2","DOI":"10.1212\/WNL.92.15_supplement.P3.2-056","volume":"92","author":"Smoot K","year":"2019","journal-title":"Neurology"},{"key":"bibr10-20552173211013831","doi-asserted-by":"publisher","DOI":"10.25259\/SNI-4-2019"},{"key":"bibr11-20552173211013831","doi-asserted-by":"publisher","DOI":"10.1177\/2055217320960510"}],"container-title":["Multiple Sclerosis Journal - Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173211013831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173211013831","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173211013831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T18:15:00Z","timestamp":1740939300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173211013831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1177\/20552173211013831"],"URL":"https:\/\/doi.org\/10.1177\/20552173211013831","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"article-number":"20552173211013831"}}